GlassScriptPhysician profile
Boyan Hadjiev
NPI 1851354997
$97,101.81
in general payments reported to CMS, 2019-2025
38 companies · $22K in 2025
The $22K reported for 2025 was more than what 92% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,119 · 2020: $11K · 2021: $15K · 2022: $19K · 2023: $7,393 · 2024: $20K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $13K · Consulting Fee: $8,683 · Travel and Lodging: $1,581 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,160.00 |
| Food and Beverage | $12,667.89 |
| Consulting Fee | $8,683.25 |
| Travel and Lodging | $1,581.17 |
| Education | $130.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $67,303.60 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Novartis Pharmaceuticals Corporation | $11,454.57 | 2019-2025 | |
| Glaxosmithkline, LLC. | $3,588.72 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $2,988.62 | 2019-2025 | |
| Amgen INC. | $2,921.26 | 2021-2025 | Tezspire, Otezla |
| Regeneron Healthcare Solutions, INC. | $1,445.65 | 2019-2025 | Dupixent |
| Pfizer INC. | $976.59 | 2019-2025 | |
| Kaleo, INC. | $762.78 | 2019-2024 | Auvi-Q |
| Csl Behring | $632.67 | 2022-2025 | Haegarda, Kcentra, Andembry |
| Optinose US, INC. | $614.58 | 2019-2025 | |
| Abbvie INC. | $579.13 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $557.22 | 2020-2025 | Stiolto Respimat, Spiriva Respimat |
| Leo Pharma INC. | $368.63 | 2022-2025 | Adbry, Anzupgo |
| Teva Pharmaceuticals USA, INC. | $366.90 | 2019-2022 | |
| Incyte Corporation | $334.12 | 2021-2024 | Opzelura |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greer Laboratories, INC. | $279.58 | 2019 | |
| Pharming Healthcare, INC. | $245.37 | 2022-2025 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $234.25 | 2020-2025 | Hyqvia |
| Sanofi-Aventis U.S. LLC | $205.02 | 2019-2025 | |
| Alk-Abello, INC | $171.08 | 2019-2025 | Odactra, Ragwitek, Grastek |
| Hikma Pharmaceuticals USA | $168.64 | 2023-2025 | Ryaltris |
| Lilly USA, LLC | $129.52 | 2024-2025 | Ebglyss |
| Eyevance Pharmaceuticals LLC | $103.01 | 2019-2021 | |
| Grifols USA, LLC | $93.99 | 2022-2024 | Xembify |
| Ionis Pharmaceuticals, INC. | $77.34 | 2025 | Dawnzera |
| Genentech USA, INC. | $77.33 | 2019-2022 | |
| Organon LLC | $61.37 | 2025 | Vtama |
| Octapharma USA, INC. | $51.14 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $44.43 | 2025 | Neffy |
| Covis Pharma Gmbh | $38.57 | 2019-2020 | |
| Phadia US INC. | $37.61 | 2021-2025 | Immunocap |
| Shire North American Group INC | $36.44 | 2019 | |
| Circassia INC. | $36.02 | 2019 | |
| Biocryst US Sales Co., LLC | $33.73 | 2025 | Orladeyo |
| Aimmune Therapeutics, INC. | $30.50 | 2022 | |
| Adma Biomanufacturing LLC | $20.75 | 2025 | |
| Merck Sharp & Dohme LLC | $17.49 | 2021 | |
| Dermavant Sciences, INC. | $13.59 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boyan Hadjiev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.